Does Preoperative Laboratory Monitoring of Antithrombotic Therapy Avoid Adverse Outcomes in Patients Undergoing Surgery or Regional Anaesthesia?

Expenditure and prescriptions twelve months to 30 June 2013. Canberra, ACT: Department of Health, Pharmaceutical Policy Branch - PBS Information Management Section; 2013 -Accessed July 2014. Available from: http://www.pbs.gov.au/info/statistics/expenditure-and-prescriptions-30-6-2013.

Douketis J.D. , Spyropoulos A.C. , Spencer F.A. , Mayr M. , Jaffer A.K. , Eckman M.H. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e326S–50S.

Butwick A. , Hass C. , Wong J. , Lyell D. , El-Sayed Y. Anticoagulant prescribing practices and anesthetic interventions among antico-agulated pregnant patients: a retrospective study. Int J Obstet Anesth 2014; 23: 238–245.

Horlocker T.T. Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy. Br J Anaesth 2011; 107 Suppl 1: i96–106.

Ortigueira M. , Capanna F. , Boehlen F. , Martinez de Tejada B. , Savoldelli G. Prolonged anti-Xa activity due to enoxaparin near the end of pregnancy. Anaesth Intensive Care 2014; 42: 668–670.

Tran H.A. , Chunilal S.D. , Harper P.L. , Tran H. , Wood E.M. , Gallus A.S. An update of consensus guidelines for warfarin reversal. Med J Aust 2013; 198: 198–199.

Weitz J.I. Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs. In: Brunton L. , Chabner B. , Knollmann B. , editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. Sydney: McGraw-Hill Medical; 2011. p. 849–876.

Kovacs M.J. , Kearon C. , Rodger M. , Anderson D.R. , Turpie A.G.G. , Bates S.M. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658–1663.

Garcia D.A. , Baglin T.P. , Weitz J.I. , Samama M.M. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e24S–43S.

Patel J.P. , Green B. , Patel R.K. , Marsh M.S. , Davies J.G. , Arya R. Population pharmacokinetics of enoxaparin during the antenatal period. Circulation 2013; 128: 1462–1469.

Sanderink Ger-Jan C.M. , Guimart C.G. , Ozoux M.L. , Jariwala N.U. , Shukla U.A. , Boutouyrie B.X. Pharmacokinetics and phar-macodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225–231.

Schulman S. New oral anticoagulant agents - general features and outcomes in subsets of patients. Thromb Haemost 2014; 111: 575–582.

Moore T.J. , Cohen M.R. , Mattison D.R. Dabigatran, bleeding, and the regulators. BMJ 2014; 349: g4517.